Photodynamic Therapy for Field Cancerization in the Skin: Where Do We Stand?

被引:2
|
作者
Bakirtzi, Katerina [1 ,2 ]
Papadimitriou, Ilias [1 ]
Vakirlis, Efstratios [1 ]
Lallas, Aimilios [1 ]
Sotiriou, Eleni [1 ]
机构
[1] Aristotle Univ Thessaloniki, Dept Dermatol & Venereol 1, Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Delfon 124,POB 54643, Thessaloniki, Greece
来源
DERMATOLOGY PRACTICAL & CONCEPTUAL | 2023年 / 13卷 / 04期
关键词
actinic keratosis; photodynamic therapy; skin field cancerization; METHYL-AMINOLEVULINATE; ACTINIC KERATOSES; 5-AMINOLEVULINIC ACID; BF-200; ALA; TRANSPLANT RECIPIENTS; RANDOMIZED-TRIAL; DOUBLE-BLIND; PHASE-III; EFFICACY; FACE;
D O I
10.5826/dpc.1304a291
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Introduction: Photodynamic therapy (PDT) with a photosensitizer is available for the treatment of multiple actinic keratoses (AKs) in a restricted skin area or, as it is established, for the field-cancerized skin.Objectives: Our review aims to present the up-to-date literature on skin field cancerization using PDT employing different topical photosensitizers, modified light delivery protocols and combination treatments to obtain excellent efficacy and safety in everyday clinical practice.Methods: We sought PubMed, MEDLINE, Scopus, OVID, Embase, Science Direct, Cochrane Library, Research Gate and Google Scholar for [(aminolevulinic acid OR aminolevulinate) AND photodynamic therapy] with (field-directed OR field cancerization, (actinic keratosis), and (efficacy OR effectiveness OR pain OR tolerability) for studies published until February 2023.Results: Advantages of PDT compared to the other field treatments, including imiquimod, 5-fluorouracil, ingenol mebutate gel and diclofenac, reported better cosmetic outcomes and greater patient satisfaction. On the other hand, some drawbacks of field PDT include pain and treatment duration. Alternate illumination methods have also been investigated, including daylight as a light source. Pretreating the affected area may enhance photosensitizer absorption leading to better therapeutic results, while combinational treatments have also been tested. Patients prefer daylight PDT to traditional light sources since it is more well-tolerated and equally effective. Even as a preventive treatment, field PDT yields promising outcomes, especially for high-risk individuals, including organ transplant recipients.Conclusions: This review provides a thorough display of the field of PDT on cancerized skin, which will facilitate physicians in applying PDT more efficiently and intuitively.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Ebola virus vaccines: Where do we stand?
    Pavot, Vincent
    CLINICAL IMMUNOLOGY, 2016, 173 : 44 - 49
  • [32] Immunotherapy in Allergic Asthma: Where do We Stand?
    Cardona, Victoria
    ALLERGY, ASTHMA, COPD, IMMUNOPHYSIOLOGY & IMMUNOREHABILITOLOGY: INNOVATIVE TECHNOLOGIES, 2018, : 25 - 32
  • [33] Male hormonal contraception: Where do we stand?
    Mahmoud, Ahmed
    T'Sjoen, Guy
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2012, 17 (03) : 179 - 186
  • [34] Subcutaneous and sublingual immunotherapy:Where do we stand?
    Ayfer Yukselen
    Seval Guneser Kendirli
    World Journal of Immunology, 2014, (03) : 130 - 140
  • [35] Daylight photodynamic therapy for field cancerization: lessons from molecular biology
    Rybarski, Max
    Schmitz, Lutz
    Novak, Ben
    Dirschka, Thomas
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2018, 153 (06): : 806 - 810
  • [36] Male CP/CPPS: where do we stand?
    Doiron, R. Christopher
    Shoskes, Daniel A.
    Nickel, J. Curtis
    WORLD JOURNAL OF UROLOGY, 2019, 37 (06) : 1015 - 1022
  • [37] Glycemic effects of simvastatin: Where do we stand?
    Razali, Nor Razida
    Huri, Hasniza Zaman
    Ibrahim, Luqman
    Vethakkan, Shireene Ratna
    Abdullah, Bashar Mudhaffar
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 54 (01)
  • [38] Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?
    Peng, Yan
    Yan, Hongxiang
    Mei, Wuxuan
    Zhang, Pengfei
    Zeng, Changchun
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (10) : 1378 - 1391
  • [39] Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
    Geraud, Arthur
    Gougis, Paul
    de Nonneville, Alexandre
    Beaufils, Mathilde
    Billon, Emilien
    Brisou, Gabriel
    Gravis, Gwenaelle
    Greillier, Laurent
    Guerin, Mathilde
    Mezni, Essia
    Mitry, Emmanuel
    Noel, Robin
    Pignon, Josephine
    Sabatier, Renaud
    Seguin, Lorene
    Spano, Jean-Philippe
    Vicier, Cecile
    Viret, Frederic
    Goncalves, Anthony
    Ciccolini, Joseph
    CANCER TREATMENT REVIEWS, 2025, 135
  • [40] Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
    Carloni, Riccardo
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Frega, Giorgio
    Di Federico, Alessandro
    Palloni, Andrea
    Di Marco, Mariacristina
    Gadaleta-Caldarola, Gennaro
    Brandi, Giovanni
    FUTURE ONCOLOGY, 2022, 18 (08) : 1023 - 1034